跳至主要内容
临床试验/NCT04059965
NCT04059965撤回不适用

AntiCoagulation Tracking InterVention and Evaluation: Using a Customized Panel Management Platform to Improve Outcomes for Patients on Anticoagulation

University of California, San Francisco0 个研究点开始时间: 2022年10月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
撤回
主要终点
Time in Therapeutic Range

研究概览

简要总结

Anticoagulants are a leading cause of acute injury from adverse drug events, leading to ~20,000 serious injuries reported to the Food and Drug Administration per year and more than 220,000 emergency department visits annually. Therefore, we propose to implement a health information technology (HIT) population management tool at two distinct anticoagulation clinics that will allow the care team to assign and track tasks essential for timely patient monitoring. We will examine its effect on anticoagulation management outcomes through a randomized trial, hypothesizing that such interventions can be effective as well as cost-effective strategies to improve patient safety in the context of anticoagulation management services.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Adults (age ≥18 years)
  • •those prescribed an anticoagulation medication at Zuckerberg San Francisco General Hospital or University of California, San Francisco Health

排除标准

  • •Minors (age<18)
  • •those not prescribed anticoagulation medication at ZSFG or UCSF Health

研究组 & 干预措施

Intervention Arm

Experimental

This cohort of patients will receive panel management through a customize software that integrates with the electronic health record

干预措施: Panel Management for Anticoagulation Therapy (Other)

Control Arm

Active Comparator

This cohort of patients will receive usual care

干预措施: Usual Care (Other)

结局指标

主要结局

Time in Therapeutic Range

时间窗: 6 months

Using the Rosendaal method, we will assess the proportion of the treatment duration that the patient's International Normalized Ratio is within the goal therapeutic range.

次要结局

  • Proportion Time in Range(6 months)
  • Time from initiation to therapeutic INR (TWTR)(Study Period (average of 2 years))
  • Adverse events(Study Period (average of 2 years))

研究者

申办方类型
Other
责任方
Sponsor

相似试验